Overview Dividends

(AVDL) Avadel Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00BDGMC594

Sodium Oxybate, Narcolepsy Treatment, LUMRYZ

Pharmaceuticals
Market Cap in USD: 2,099m
IPO / Inception: 1996-06-07
Return 12m vs S&P 500: 77.6%

EPS (Earnings per Share)

EPS (Earnings per Share) of AVDL over the last years for every Quarter: "2020-12": -0.19, "2021-03": -0.23, "2021-06": -0.33, "2021-09": -0.38, "2021-12": -0.38, "2022-03": -0.45, "2022-06": -1.01, "2022-09": -0.33, "2022-12": -0.46, "2023-03": -0.48, "2023-06": -0.83, "2023-09": -0.41, "2023-12": -0.29, "2024-03": -0.3, "2024-06": -0.14, "2024-09": -0.0273, "2024-12": -0.05, "2025-03": -0.05, "2025-06": 0.1, "2025-09": 0.0002,
EPS CAGR: 12.87%
EPS Trend: 77.9%
Last SUE: -1.40
Qual. Beats: 0

Revenue

Revenue of AVDL over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 1.496, 2023-09: 7.014, 2023-12: 19.453, 2024-03: 27.178, 2024-06: 41.504, 2024-09: 50.025, 2024-12: 50.41, 2025-03: 52.511, 2025-06: 68.129, 2025-09: 77.467,
Rev. CAGR: 197.36%
Rev. Trend: 94.4%
Last SUE: 1.12
Qual. Beats: 2

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 61.9%
Value at Risk 5%th 74.4%
Relative Tail Risk -26.90%
Reward TTM
Sharpe Ratio 1.43
Alpha 84.72
CAGR/Max DD 0.68
Character TTM
Hurst Exponent 0.604
Beta 0.816
Beta Downside 1.225
Drawdowns 3y
Max DD 64.98%
Mean DD 23.36%
Median DD 17.94%

Description: AVDL Avadel Pharmaceuticals November 17, 2025

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a Dublin-based biopharma focused on developing novel treatments for central nervous system disorders. Its lead asset, LUMRYZ™ (sodium oxybate), is in a Phase 3 trial targeting cataplexy and excessive daytime sleepiness in narcolepsy patients aged seven and older. The company, originally Flamel Technologies SA, rebranded to Avadel in January 2017 and has operated as a public entity since its 2015 incorporation.

Key metrics as of the latest filing show a cash runway of roughly $120 million, giving the firm >12 months of operating liquidity without additional financing. The narcolepsy market is projected to grow at a CAGR of ~6% through 2028, driven by increasing diagnosis rates and unmet therapeutic needs. Avadel’s R&D spend represents about 30% of total revenue, reflecting its pipeline-heavy strategy, while the broader CNS drug sector benefits from higher reimbursement rates and a favorable FDA “fast-track” environment for sleep-disorder indications.

For a deeper dive into Avadel’s valuation assumptions and scenario analysis, you might find the ValueRay platform’s detailed model worth reviewing.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (-278.0k TTM) > 0 and > 6% of Revenue (6% = 14.9m TTM)
FCFTA 0.18 (>2.0%) and ΔFCFTA 70.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 44.16% (prev 61.14%; Δ -16.99pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.18 (>3.0%) and CFO 35.6m > Net Income -278.0k (YES >=105%, WARN >=100%)
Net Debt (-42.4m) to EBITDA (10.1m) ratio: -4.19 <= 3.0 (WARN <= 3.5)
Current Ratio 2.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (101.3m) change vs 12m ago 5.17% (target <= -2.0% for YES)
Gross Margin 94.47% (prev 91.92%; Δ 2.54pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 139.0% (prev 87.30%; Δ 51.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 0.66 (EBITDA TTM 10.1m / Interest Expense TTM 9.71m) >= 6 (WARN >= 3)

Altman Z'' -17.48

(A) 0.55 = (Total Current Assets 172.2m - Total Current Liabilities 62.5m) / Total Assets 199.4m
(B) -3.96 = Retained Earnings (Balance) -789.6m / Total Assets 199.4m
warn (B) unusual magnitude: -3.96 — check mapping/units
(C) 0.04 = EBIT TTM 6.45m / Avg Total Assets 178.9m
(D) -8.02 = Book Value of Equity -812.2m / Total Liabilities 101.2m
Total Rating: -17.48 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 63.69

1. Piotroski 6.0pt
2. FCF Yield 1.73%
3. FCF Margin 14.25%
4. Debt/Equity 0.38
5. Debt/Ebitda -4.19
6. ROIC - WACC (= -6.07)%
7. RoE -0.33%
8. Rev. Trend 94.38%
9. EPS Trend 77.87%

What is the price of AVDL shares?

As of December 19, 2025, the stock is trading at USD 21.42 with a total of 1,387,188 shares traded.
Over the past week, the price has changed by +0.14%, over one month by -6.63%, over three months by +31.98% and over the past year by +107.36%.

Is AVDL a buy, sell or hold?

Avadel Pharmaceuticals has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy AVDL.
  • Strong Buy: 6
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the AVDL price?

Issuer Target Up/Down from current
Wallstreet Target Price 20.9 -2.2%
Analysts Target Price 20.9 -2.2%
ValueRay Target Price 28 30.5%

AVDL Fundamental Data Overview December 13, 2025

Market Cap USD = 2.10b (2.10b USD * 1.0 USD.USD)
P/E Forward = 16.6667
P/S = 8.4471
P/B = 21.3717
P/EG = 0.07
Beta = 1.632
Revenue TTM = 248.5m USD
EBIT TTM = 6.45m USD
EBITDA TTM = 10.1m USD
Long Term Debt = 2.55m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 740.0k USD (from shortTermDebt, last quarter)
Debt = 37.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -42.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.05b USD (2.10b + Debt 37.4m - CCE 91.6m)
Interest Coverage Ratio = 0.66 (Ebit TTM 6.45m / Interest Expense TTM 9.71m)
FCF Yield = 1.73% (FCF TTM 35.4m / Enterprise Value 2.05b)
FCF Margin = 14.25% (FCF TTM 35.4m / Revenue TTM 248.5m)
Net Margin = -0.11% (Net Income TTM -278.0k / Revenue TTM 248.5m)
Gross Margin = 94.47% ((Revenue TTM 248.5m - Cost of Revenue TTM 13.8m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 90.66%)
Tobins Q-Ratio = 10.25 (Enterprise Value 2.05b / Total Assets 199.4m)
Interest Expense / Debt = 6.46% (Interest Expense 2.42m / Debt 37.4m)
Taxrate = 62.96% (34.0k / 54.0k)
NOPAT = 2.39m (EBIT 6.45m * (1 - 62.96%))
Current Ratio = 2.76 (Total Current Assets 172.2m / Total Current Liabilities 62.5m)
Debt / Equity = 0.38 (Debt 37.4m / totalStockholderEquity, last quarter 98.2m)
Debt / EBITDA = -4.19 (Net Debt -42.4m / EBITDA 10.1m)
Debt / FCF = -1.20 (Net Debt -42.4m / FCF TTM 35.4m)
Total Stockholder Equity = 84.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.14% (Net Income -278.0k / Total Assets 199.4m)
RoE = -0.33% (Net Income TTM -278.0k / Total Stockholder Equity 84.2m)
RoCE = 7.44% (EBIT 6.45m / Capital Employed (Equity 84.2m + L.T.Debt 2.55m))
RoIC = 2.84% (NOPAT 2.39m / Invested Capital 84.2m)
WACC = 8.90% (E(2.10b)/V(2.14b) * Re(9.02%) + D(37.4m)/V(2.14b) * Rd(6.46%) * (1-Tc(0.63)))
Discount Rate = 9.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 8.56%
[DCF Debug] Terminal Value 72.49% ; FCFE base≈35.4m ; Y1≈31.1m ; Y5≈25.4m
Fair Price DCF = 3.97 (DCF Value 389.1m / Shares Outstanding 98.1m; 5y FCF grow -15.00% → 3.0% )
EPS Correlation: 77.87 | EPS CAGR: 12.87% | SUE: -1.40 | # QB: 0
Revenue Correlation: 94.38 | Revenue CAGR: 197.4% | SUE: 1.12 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.13 | Chg30d=+0.018 | Revisions Net=+0 | Analysts=5
EPS next Year (2026-12-31): EPS=0.78 | Chg30d=+0.024 | Revisions Net=-1 | Growth EPS=+182.6% | Growth Revenue=+29.3%

Additional Sources for AVDL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle